Shannon Thyme Klinger - 27 Feb 2026 Form 4 Insider Report for Moderna, Inc. (MRNA)

Role
Chief Legal Officer
Signature
/s/ James Dillon, as Attorney-in-Fact
Issuer symbol
MRNA
Transactions as of
27 Feb 2026
Net transactions value
-$546,288
Form type
4
Filing time
03 Mar 2026, 16:10:53 UTC
Previous filing
13 Feb 2026
Next filing
06 Mar 2026
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Klinger Shannon Thyme Chief Legal Officer C/O MODERNA, INC., 325 BINNEY STREET, CAMBRIDGE /s/ James Dillon, as Attorney-in-Fact 03 Mar 2026 0001866132

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction MRNA Common Stock Options Exercise +233 +0.43% 54,760 27 Feb 2026 Direct F1
transaction MRNA Common Stock Tax liability $5,843 -113 -0.21% $51.71 54,647 27 Feb 2026 Direct F2
transaction MRNA Common Stock Options Exercise +329 +0.6% 54,976 27 Feb 2026 Direct F1
transaction MRNA Common Stock Tax liability $8,274 -160 -0.29% $51.71 54,816 27 Feb 2026 Direct F2
transaction MRNA Common Stock Options Exercise +774 +1.4% 55,590 27 Feb 2026 Direct F1
transaction MRNA Common Stock Tax liability $19,391 -375 -0.67% $51.71 55,215 27 Feb 2026 Direct F2
transaction MRNA Common Stock Options Exercise +8,663 +16% 63,878 27 Feb 2026 Direct F1
transaction MRNA Common Stock Tax liability $216,613 -4,189 -6.6% $51.71 59,689 27 Feb 2026 Direct F2
transaction MRNA Common Stock Options Exercise $429,880 +13,885 +23% $30.96 73,574 02 Mar 2026 Direct F3
transaction MRNA Common Stock Sale $726,047 -13,885 -19% $52.29 59,689 02 Mar 2026 Direct F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction MRNA Restricted Stock Units Options Exercise $0 -233 -100% $0.000000 0 27 Feb 2026 Common Stock 233 Direct F1, F4
transaction MRNA Restricted Stock Units Options Exercise $0 -329 -20% $0.000000 1,315 27 Feb 2026 Common Stock 329 Direct F1, F5
transaction MRNA Restricted Stock Units Options Exercise $0 -774 -11% $0.000000 6,189 27 Feb 2026 Common Stock 774 Direct F1, F6
transaction MRNA Restricted Stock Units Options Exercise $0 -8,663 -25% $0.000000 25,992 27 Feb 2026 Common Stock 8,663 Direct F1, F7
transaction MRNA Stock Option (Right to Buy) Award $0 +29,275 $0.000000 29,275 01 Mar 2026 Common Stock 29,275 $53.57 Direct F8
transaction MRNA Restricted Stock Units Award $0 +38,553 $0.000000 38,553 01 Mar 2026 Common Stock 38,553 Direct F1, F9
transaction MRNA Stock Option (Right to Buy) Options Exercise $0 -13,885 -25% $0.000000 41,658 02 Mar 2026 Common Stock 13,885 $30.96 Direct F3, F10
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 Restricted stock units convert into common stock on a one-for-one basis.
F2 Represents shares withheld at the election of the Reporting Person to satisfy tax withholding obligations in connection with the vest of restricted stock units.
F3 The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on September 9, 2025.
F4 25% of the shares subject to this restricted stock unit award vested on March 1, 2023 with the remainder vesting in twelve (12) equal quarterly installments thereafter.
F5 25% of the shares subject to this restricted stock unit award vested on February 28, 2024 with the remainder vesting in twelve (12) equal quarterly installments thereafter.
F6 25% of the shares subject to this restricted stock unit award vested on February 27, 2025 with the remainder vesting in twelve (12) equal quarterly installments thereafter.
F7 25% of the shares subject to this restricted stock unit award vested on March 1, 2026 with the remainder vesting in twelve (12) equal quarterly installments thereafter.
F8 25% of this option will vest and become exercisable on March 1, 2027 with the remainder vesting in twelve (12) equal quarterly installments thereafter.
F9 25% of the shares subject to this restricted stock unit award will vest on March 1, 2027 with the remainder vesting in twelve (12) equal quarterly installments thereafter.
F10 25% of this option vested and became exercisable on March 1, 2026 with the remainder vesting in twelve (12) equal quarterly installments thereafter.